Effect of sequential applications of topical tacrolimus and topical corticosteroids in the treatment of pediatric atopic dermatitis: An open-label pilot study

2009 ◽  
Vol 60 (2) ◽  
pp. 212-217 ◽  
Author(s):  
Yasuo Kubota ◽  
Kozo Yoneda ◽  
Kozo Nakai ◽  
Junko Katsuura ◽  
Tetsuya Moriue ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Pilot Study ◽  
Open Label ◽  
Topical Tacrolimus ◽  
Topical Corticosteroids

Open-label, pilot study examining sequential therapy with oral tacrolimus and topical tacrolimus for severe atopic dermatitis

2012 ◽  
Vol 67 (4) ◽  
pp. 636-641 ◽  
Author(s):  
Terrence Colin Keaney ◽  
Tina Bhutani ◽  
Priya Sivanesan ◽  
Grace D. Bandow ◽  
Sari Beth Weinstein ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Pilot Study ◽  
Sequential Therapy ◽  
Severe Atopic Dermatitis ◽  
Open Label ◽  
Topical Tacrolimus

Pancreatic Enzyme Supplementation in Patients with Atopic Dermatitis and Food Allergies: An Open-Label Pilot Study

2018 ◽  
Vol 21 (1) ◽  
pp. 41-45 ◽  
Author(s):  
Sanford Singer ◽  
Jamie Koenekoop ◽  
Jonathan Meddings ◽  
Julie Powell ◽  
Anne Desroches ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Pilot Study ◽  
Pancreatic Enzyme ◽  
Food Allergies ◽  
Open Label ◽  
Enzyme Supplementation

Safety and Efficacy of Tacrolimus Ointment 0.1% (Protopic™) in Atopic Dermatitis: A Canadian Open-Label Multicenter Study

2004 ◽  
Vol 8 (4) ◽  
pp. 213-219 ◽  
Author(s):  
Jerry Tan ◽  
Richard Langley
Keyword(s):  
Atopic Dermatitis ◽  
Severe Disease ◽  
Multicenter Trial ◽  
Application Site ◽  
Skin Infections ◽  
Open Label ◽  
Safety And Efficacy ◽  
Topical Tacrolimus ◽  
Efficacy Parameters ◽  
Study Sites

Background: Most previously published trials of topical tacrolimus in atopic dermatitis were of relatively short duration and comprised a limited population with moderate-to-severe disease. Objective: The goal of the study was to evaluate the safety and efficacy over a 6-month period of tacrolimus 0.1% ointment in children and adults with a broader severity spectrum of atopic dermatitis. Methods: An open-label multicenter trial in patients 2 years and older was used. Primary safety and tolerability assessments included skin infection and application site adverse events. Efficacy parameters were body surface area involvement, pruritus score, and overall reponse. Results: There were 240 patients recruited at 23 study sites. Significant improvement from baseline was noted for all efficacy endpoints in both pediatric and adult patients. Skin infections occurred in 26% of patients. Burning sensation with product application, reported by 38% of patients, was transient and of mild-to-moderate severity in the majority. Conclusion: Tacrolimus 0.1% ointment was safe, well tolerated, and efficacious in treatment of atopic dermatitis in children and adults over six months.

Topical Tacrolimus 0.03% Ointment for Intractable Allergic Conjunctivitis: An Open-Label Pilot Study

2008 ◽  
Vol 33 (7) ◽  
pp. 545-549 ◽  
Author(s):  
Liat Attas-Fox ◽  
Yaniv Barkana ◽  
Vladimir Iskhakov ◽  
Svetlana Rayvich ◽  
Yariv Gerber ◽  
...  
Keyword(s):  
Pilot Study ◽  
Allergic Conjunctivitis ◽  
Open Label ◽  
Topical Tacrolimus

scholarly journals A Randomized, Open-Label, Multicenter Trial of Topical Tacrolimus for the Treatment of Pruritis in Patients with Atopic Dermatitis

2012 ◽  
Vol 24 (2) ◽  
pp. 144 ◽  
Author(s):  
Satoshi Takeuchi ◽  
Hidehisa Saeki ◽  
Shoji Tokunaga ◽  
Makoto Sugaya ◽  
Hanako Ohmatsu ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Multicenter Trial ◽  
Open Label ◽  
Topical Tacrolimus
Sign in / Sign up

Export Citation Format

Share Document